|
| A systematic review of the efficacy and safety of Chinese patent medicine in the treatment of coronary revascularization |
| Hits 1694 Download times 1619 Received:November 25, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2018.01.06 |
| Key Words
Chinese patent medicine;postoperative of coronary revascularization;system evaluation;Meta analysis |
| Author Name | Affiliation | E-mail | | TANG Gengyi | Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | TANG E | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | ZHAO Guifeng | The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | 13920973198@139.com |
|
| Abstract
|
| [Objective] Evaluation of the clinical efficacy and safety of Western medicine in the treatment of postoperative of coronary revascularization with oral proprietary Chinese patent medicine and conventional Western medicine alone.[Methods] A randomized controlled trials were conducted to evaluate the efficacy of Western medicine in the treatment of postoperative of coronary revascularization with oral proprietary Chinese patent medicine and conventional Western medicine. According to the related methods of Cochrane collaboration network, the quality of the literature and the effective correlation Data were Meta analysis.[Results] A total of 15 studies were included, including 1 350 patients. The results showed that Western medicine combined with oral Chinese medicine can not only improve the coronary revascularization in patients with postoperative traditional Chinese medicine syndrome, clinical total curative effect, angina pectoris and ECG curative effect, reduce the restenosis rate, increase cardiac output, but also can inhibit the expression of inflammatory factor.[Conclusion] Compare with Western medicine, Western medicine combine with oral proprietary Chinese patent medicine can be used to treat postoperative of coronary revascularization in patients with acute mycocardial infarction. |
|
|
|
|
|
|
|
